Basecamp Research raised $140 million in an oversubscribed Series C to train its next-generation EDEN foundation models and apply them to in vivo cell therapies across disease areas, the company announced. Basecamp said its approach targets reprogramming inside the body rather than ex vivo manufacturing, aiming to reduce complexity and cost. The funding is intended to support next-generation EDEN model training and continued development of therapeutics designed with large serine recombinases delivered precisely to implement complex DNA changes. Basecamp highlighted preclinical results across multiple modalities and disease indications. Anthropic and other technology-forward investors participated, and Basecamp previously appointed Richard Pearce as chief business officer to expand partnerships with biopharma. CEO Glen Gowers described the work as bringing AI-based therapeutic design closer to patients who lack alternatives. The financing reinforces momentum for AI-native drug discovery companies that can credibly connect model outputs to buildable biology and scalable manufacturing.